6302. Mupirocin

Description and references

Major component of the pseudomonic acids, q.v., an antibiotic complex produced by Pseudomonas fluorescens NCIB 10586. Isoln and characterization: A. T. Fuller et al., Nature 234, 416 (1971); K. D. Barrow, G. Mellows, DE 2227739; eidem, US 3977943; eidem, US 4071536 (1973, 1976, 1978 all to Beecham). Purification: P. J. O'Hanlon et al., DE 2842358; eidem, US 4222942 (1979, 1980 both to Beecham). Structure: E. B. Chain, G. Mellows, Chem. Commun. 1974, 847; eidem, J. Chem. Soc. Perkin Trans. 1 1977, 294. Absolute configuration: R. G. Alexander et al., ibid. 1978, 561. Prepn from methyl pseudomonate C: eidem, Tetrahedron Lett. 22, 2059 (1981). Total syntheses of (±)-form: B. B. Snider, G. B. Phillips, J. Am. Chem. Soc. 104, 1113 (1982); B. B. Snider et al., J. Org. Chem. 48, 3003 (1983). Biosynthesis: T. C. Feline et al., J. Chem. Soc. Perkin Trans. 1 1977, 309. Effect of pH on chemical stability and antibacterial activity: J. P. Clayton et al., ibid. 1979, 838. Inhibition of bacterial protein synthesis: J. Hughes, G. Mellows, J. Antibiot. 31, 330 (1978); of isoleucyl-tRNA synthetase: eidem, Biochem. J. 176, 305 (1978); eidem, ibid. 191, 209 (1980). In vitro antibacterial spectrum: R. Sutherland et al., Antimicrob. Agents Chemother. 27, 495 (1985); M. W. Casewell, R. L. R. Hill, J. Antimicrob. Chemother. 15, 523 (1985). Antimycoplasmal activity in vitro: R. M. Banks et al., J. Antibiot. 41, 609 (1988). Clinical evaluations: G. D. Reilly, R. C. Spencer, ibid. 13, 295 (1984); M. W. Casewell, R. L. R. Hill, ibid. 17, 365 (1986). Reviews: A. Ward, D. M. Campoli-Richards, Drugs 32, 425-444 (1986); M. W. Casewell, R. L. R. Hill, J. Antimicrob. Chemother. 19, 1-5 (1987).

Properties